Henry Schein (HSIC)
Health Care · $9.7B market cap · SEC CIK 0001000228
fundamentals score out of 100
Next reports on Nov 2, 2026, before the open, with analysts expecting $1.38 in earnings per share.
The case for HSIC
Nothing in the numbers stands out as a strength.
The case against
- Net margin of 3.0% leaves very little room for error.
- Weakest against its peers: revenue growth of +6.5% is slower than 62% of Health Care companies.
What the score is made of
Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. It describes the last filing and the current price. It is not a forecast.
| Valuewhat you pay for the earnings, sales, assets and cash | 69 |
|---|---|
| Growthhow fast revenue and earnings are moving, this year and over five | 45 |
| Profitabilityhow much of the revenue becomes profit, and how much of that is cash | 37 |
| Momentumhow the price has behaved lately | 75 |
| Stabilityhow violently it moves, what it owes and what it pays you | 66 |
- Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.
Key numbers
| Price / earnings | 24.1× |
|---|---|
| Price / book | 3.04× |
| Price / sales | 0.7× |
| Revenue growth (YoY) | +6.5% |
| EPS growth (YoY) | +10.3% |
| Gross margin | 31% |
| Operating margin | 5% |
| Net margin | 3% |
| Return on equity | 12% |
| Debt / equity | 1.10× |
| Current ratio | 1.32 |
| Dividend yield | none |
| Beta | 0.87 |
| 52-week range | $61.95 – $92.18 |
| Position in that range | 84% of the way up |
| 3-month return | +6.6% |
| 1-year return | +25.6% |
Five years of financials, as filed
Pulled from Henry Schein's XBRL filings on SEC EDGAR. Italic rows are derived from the rows above.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $13.2B | $12.7B | $12.3B | $12.6B | $12.4B |
| Gross profit | $4.1B | $4.0B | $3.9B | $3.8B | $3.7B |
| Operating income | $653M | $621M | $615M | $747M | $852M |
| Net income | $419M | $398M | $436M | $566M | $660M |
| Operating cash flow | $712M | $848M | $500M | $602M | $710M |
| Capital expenditure | $139M | $148M | $147M | $96.0M | $79.0M |
| Total assets | $11.2B | $10.2B | $10.6B | $8.6B | $8.5B |
| Total liabilities | $6.4B | $5.4B | $5.4B | $3.9B | $3.8B |
| Shareholder equity | $3.2B | $3.4B | $3.7B | $3.4B | $3.4B |
| Cash | $156M | $122M | $171M | $117M | $118M |
| Long-term debt | — | — | — | $1.0B | $822M |
| Free cash flow | $573M | $700M | $353M | $506M | $631M |
| Gross margin | 31.1% | 31.7% | 31.3% | 30.3% | 29.6% |
| Operating margin | 5.0% | 4.9% | 5.0% | 5.9% | 6.9% |
| Net margin | 3.2% | 3.1% | 3.5% | 4.5% | 5.3% |
| Diluted shares | 122M | 128M | 132M | 138M | 142M |
Share count is down 14.1% over 4 years. Buybacks have been shrinking the pie.
What Henry Schein says it does
, Other Executive Management . Our Vice President, Global CISO, who also serves as Vice President and Head of the Office of Cyber Security, has over 30 years of experience leading global cybersecurity and technology programs in large and complex corporations, and holds a Certified Information Systems Security Professional and a Certified Information Systems Auditor certification. He also received a BS, Information Technology and Security from Baker College. The cybersecurity risk mitigation strategy is also overseen by senior managers who are members of our Executive Steering Committee, comprised of the Company’s most senior technology, legal and internal auditing officers. Our CEO is regularly briefed on issues, incidents, and developments, and our Board oversees our risk mitigation strategy principally through its Audit Committee and Regulatory, Compliance and Cybersecurity Committee, as described in more detail below. Our…
Risk factors HSIC lists in its 10-K
- embodying our values to achieve our collective goals with excellence
- Information about our Executive Officers
- We are dependent upon third parties for the manufacture/supply of a significant volume of our products and
- where we manufacture products, we are dependent upon third parties
- We may be unsuccessful in achieving our strategic growth objectives
- Our business could be affected by the Strategic Partnership Agreement with KKR
- Our future growth (especially for our Global Technology and Global Specialty Products segments) is dependent
- upon our ability to develop or acquire and maintain and protect
- technologies that achieve market acceptance with acceptable margins
- Risks inherent in acquisitions, dispositions and joint ventures could
- Certain provisions in our governing documents and other documents to
- third parties from seeking to acquire us that might otherwise result
- over the market price of their shares
- Adverse changes in supplier rebates or other purchasing incentives